NCT07560111
A Phase II Study of GC101 in NSCLC
레지스트리 요약
- 진행 상태
- 모집중 (RECRUITING)
- 질환/조건
- Non Small Cell Lung Cancer
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 2
- 목적
- 치료
- 중재 유형
- 생물학적 제제
- 개입·치료
- Autologous Tumor Infiltrating Lymphocytes
- Lead Sponsor
- Shanghai Juncell Therapeutics (산업계)
캐시 시각: 2026-08-06 08:36:53
요약
28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.
